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Fluorochemicals used in food packaging 
inhibit male sex hormone synthesis
Results
Hormone profiles, including eight steroid hormones, generally showed that 8:2 diPAPS, 8:2
monoPAPS and 8:2 FTOH led to decreases in testosterone, dehydroepiandrosterone, and
androstenedione in the H295R steroidogenesis assay. Decreases were observed for
progesterone and 17-OH-progesterone as well. None of the compounds showed effects in the
AR reporter gene assay.
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Background & Aim
Polyfluoroalkyl phosphate surfactants (PAPS) are widely used in food contact materials (FCMs)
of paper and board and have recently been detected in 57 % of investigated materials. Human
exposure occurs as PAPS have been measured in blood; however knowledge is lacking on the
toxicology of PAPS. Metabolic products of PAPS, fluorotelomer alcohol (FTOH) and
perfluorocarboxylic acids (PFCAs) have shown potential to interfere with the endocrine system
and thus the aim of this study was to elucidate the effects of six fluorochemicals on sex hormone
synthesis and androgen receptor (AR) activation in vitro. Four PAPS and two metabolites,
perfluorooctanoic acid (PFOA) and 8:2 fluorotelomer alcohol (8:2 FTOH) were tested.
Metabolic pathway of polyfluoroalkyl phosphate surfactants (PAPS) in rat, mice and isolated rat hepatocytes into fluorotelomer alcohol (FTOH) and
perfluorinated carboxylic acids (PFCAs). RF1, RF2 and RF3 represent fully fluorinated carbon chains of varying lengths.
Materials and Methods
Materials and methods are described in detail in the paper Fluorochemicals used in food packaging inhibit male sex hormone
synthesis (Rosenmai et al., 2012). The tested compounds include 8:2 triPAPS, 10:2 PAPS, 8:2 diPAPS and 8:2 monoPAPS and
the metabolites, 8:2 FTOH and PFOA. H295R steroidogenesis assay. The H295R cell line was cultured for 24 h with
successive test compound exposure for 48 h. Exposure concentrations ranged from 1.6 - 50.0 µM. After 48 h exposure the
supernatant was sampled for hormone analysis and cell viability was tested. Hormones were extracted from cell supernatants by
SPE and were measured both by time-resolved fluoroimmunoassays and HPLC-MS/MS. Effects on gene expression were
assessed by qRT-PCR. mRNA isolation and conversion to cDNA were performed with TaqMan® Fast Cells-to-CTTM Kit. cDNA
was analyzed on a PCR system using TaqMan® Gene Expression Assays. Androgen receptor reporter gene assay. The assay
was performed as previously described by Vinggaard et al. (2002). All plasmids were generous gifts from Dr. Albert Brinkmann
(Erasmus University, Rotterdam). Test chemicals were added leading to final exposure concentrations ranging from 0.2 – 50.0
µM on agonism, antagonism and toxicity plates.
Conclusion
Overall, the results demonstrate that of the tested endpoints interference with
steroidogenesis is the main target of the test compounds. Specifically, fluorochemicals used
in food packaging and their metabolites can affect steroidogenesis through decreased Bzrp
and increased CYP19 gene expression causing lower androgen and higher estrogen levels.
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These findings indicate that of the two tested endpoints interference with hormone synthesis is
the main mechanism of effect. The characteristic hormone profiles with exposure indicated that
a step prior to progestagen and androgen synthesis had been affected. Gene expression
analysis of StAR, Bzrp, CYP11A, CYP17, CYP21 and CYP19 mRNA showed a decrease in
Bzrp mRNA levels for 8:2 monoPAPS and 8:2 FTOH indicating interference with cholesterol
transport to the inner mitochondria.
Cortisol, estrone and 17β-estradiol levels were in several cases increased with exposure. In
accordance with these data CYP19 gene expression increased with 8:2 diPAPS, 8:2
monoPAPS and 8:2 FTOH exposures indicating that this is a contributing factor to the
decreased androgen and the increased estrogen levels.
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Overview of hormone effects in the H295R steroidogenesis assay. The qualitative effect (QE) (↓ or ↑), the lowest observable effect
concentration (LOEC) and the tentative efficacy (Emax) given in % change are shown. All values have a significance level of p < 0.05. a)
immunoassay data, b) HPLC-MS/MS data.
8:2 FTOH exposure and the hormone
profile. For further description see legend
for 8:2 monoPAPS hormone profile.
8:2 monoPAPS exposure and the
hormone profile. Concentrations are given
in µM and response in fold change.
Concentration-effect relationship for
progesterone, testosterone and 17β-
estradiol are based on immunoassay data.
The concentration-effect relationships for
the remaining hormones are based on
HPLC-MS/MS data. Bar windows (grey,
green and red) represent expression of
genes examined. Arrow up (↑) indicates an
increase in the relative level of mRNA,
arrow down (↓) represents a decrease in the
relative level of mRNA and n.s. indicates
that no statistically significant change was
observed.
8:2 triPAPS 10:2 diPAPS 8:2 diPAPS 8:2 monoPAPS 8:2 FTOH PFOA
Progesteronea QE ↓ ↓ ↓ ↓ ↓ n.s.
LOEC (µM) 12.5⁪ 50 3.1 50 3.1 n.s.
Emax (%) 26 ± 10 22 ± 16 60 ± 14 42 ± 10 45 ± 18 n.s.
17-OH- Progesteroneb QE ↓ ↓ ↓ ↓ ↓ n.s.
LOEC (µM) 12.5⁪ 3.1 12.5 3.1 3.1 n.s.
Emax (%) 14 ± 6 28 ± 3 50 ± 10 67 ± 3 55 ± 6 n.s.
Cortisolb QE n.s. ↓ ↑ n.s. n.s. n.s.
LOEC (µM) n.s. 3.1⁪ 50 n.s n.s. n.s.
Emax (%) n.s. 25 ± 15 38 ± 13 n.s. n.s. n.s.
DHEAb QE n.s. ↓ ↓ ↓ ↓ n.s.
LOEC (µM) n.s. 3.1 50 12.5 12.5⁪ n.s.
Emax (%) n.s. 29 ± 3 56 ± 8 72 ± 3 39 ± 9 n.s.
Androstenedioneb QE n.s. ↓ ↓ ↓ ↓ ↓
LOEC (µM) n.s. 12.5 12.5 12.5 3.1 12.5⁪
Emax (%) n.s. 17 ± 3 45 ± 6 65 ± 3 54 ± 4 19 ± 9
Testosteronea QE ↓ n.s. ↓ ↓ ↓ n.s.
LOEC (µM) 50 n.s. 25 25 3.1 n.s.
Emax (%) 34 ± 21 n.s. 63 ± 10 56 ± 20 53 ± 16 n.s.
Estroneb QE ↑ ↑ ↑ ↑ ↑ ↑
LOEC (µM) 12.5 50 50 50 12.5⁪ 12.5
Emax (%) 34 ± 8 30 ± 11 121 ± 9 137 ± 82 146 ± 24 75 ± 9
17β-estradiola QE n.s. n.s. n.s. n.s. ↑ ↓/↑
LOEC (µM) n.s. n.s. n.s. n.s. 12.5 1.6/50
Emax (%) n.s. n.s. n.s. n.s. 41 ± 19 24 ± 19/17 ± 22
